365 results on '"Mohile, Nimish A."'
Search Results
102. Chapter 37 - Chemotherapy for Glioneuronal Tumors
103. Time to Treatment Initiation and Clinical Outcomes in High-Grade Glioma Patients Admitted to Inpatient Rehabilitation: A Retrospective Study
104. Clinical neuro-oncology for the neurologist
105. INNV-09. CLINICAL EFFICACY OF TUMOR TREATING FIELDS FOR NEWLY DIAGNOSED GLIOBLASTOMA
106. QOLP-26. PATIENT REPORTED SOCIAL FUNCTION AND SURVIVAL IN GLIOMA PATIENTS
107. LTBK-08. TOCA 511 & TOCA FC VERSUS STANDARD OF CARE IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA
108. Epilepsy education in gliomas: engaging patients and caregivers to improve care
109. Clinical efficacy of tumor-treating fields for newly diagnosed glioblastoma.
110. The effect of structured exercise during chemotherapy on chemotherapy-induced peripheral neuropathy (CIPN): A role for interoceptive brain circuitry.
111. Feasibility of a Structured Tumor-related Epilepsy Education Intervention in Adult Gliomas (P1.6-014)
112. Treatment-Related Decisions in Malignant Gliomas: A Feasibility Study (S30.008)
113. Severe radiation-induced leukoencephalopathy: Case report and literature review
114. Response to Crevenna and Ashbury, Vallance and Bolam, and Crevenna and Keilani regarding the effects of exercise on chemotherapy-induced peripheral neuropathy
115. Wireless transcutaneous electrical nerve stimulation device for chemotherapy-induced peripheral neuropathy: an open-label feasibility study
116. Durable response to bevacizumab in adults with recurrent pilocytic astrocytoma
117. Glioblastoma in 140 characters
118. Durable response to bevacizumab in adults with recurrent pilocytic astrocytoma (P4.163)
119. Quality improvement in neurology: Neuro-Oncology Quality Measurement Set
120. A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913
121. Chemotherapy-induced peripheral neuropathy clinical trials
122. Final results from the dose-escalation stage of a phase 1/2 trial of TPI 287, a brain penetrable microtubule inhibitor, plus bevacizumab in patients with recurrent glioblastoma.
123. A longitudinal brain fMRI study of chemotherapy-induced peripheral neuropathy in 50 breast cancer patients.
124. Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma
125. U.S. Burden of Hospital Admissions and Utilization of Hospice Care for Patients with Malignant Brain Tumor (P4.326)
126. Early Palliative Care Consultation in Glioblastoma (P1.165)
127. Acute care in glioblastoma: the burden and the consequences
128. ACTR-47. TPI 287, A BRAIN PENETRABLE ANTI-MICROTUBULE AGENT, PLUS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA: RESULTS FROM A DOSE ESCALATION PHASE 1/2 CLINICAL TRIAL
129. Caregiver time burden in newly diagnosed glioblastoma: A prospective analysis.
130. Palliative and end-of-life care in glioblastoma: defining and measuring opportunities to improve care
131. Survival of Secondary Central Nervous System Lymphoma Patients in the Rituximab Era
132. Abstract 3452: Antidepressant use and risk of central nervous system metastasis
133. Painful chemotherapy-induced peripheral neuropathy: lack of treatment efficacy or the wrong clinical trial methodology?
134. Solving the riddle of glioblastoma
135. Phase 1/2 trial of bevacizumab plus TPI 287, a brain penetrable anti-microtubule agent, in patients with recurrent glioblastoma.
136. Patterns of End of Life Care in a Retrospective Cohort of Glioblastoma Patients (P4.243)
137. Acute Care Utilization in Glioblastoma (GBM): A descriptive analysis of causes, burden and outcomes (S34.008)
138. Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial.
139. HCP-16POPULATION-BASED SURVIVAL RATES FROM HIGH GRADE GLIOMA (HGG) ARE NOT IMPROVED BY INCREASED CHEMOTHERAPY USE
140. ATCT-27NRG ONCOLOGY/RTOG 0929: A RANDOMIZED PHASE I/II STUDY OF ABT-888IN COMBINATION WITH TEMOZOLOMIDE IN RECURRENT TEMOZOLOMIDE RESISTANT GLIOBLASTOMA
141. ATNT-08CB-017: A PHASE 1/2 TRIAL OF BEVACIZUMAB PLUS TPI 287, A NOVEL BRAIN PENETRABLE ANTI-MICROTUBULE AGENT, IN PATIENTS WITH RECURRENT GLIOBLASTOMA NAÏVE TO ANTI-ANGIOGENIC THERAPY
142. ATCT-15CB-018: A PHASE 2 TRIAL OF BEVACIZUMAB PLUS TPI 287, A NOVEL BRAIN PENETRABLE ANTI-MICROTUBULE AGENT, IN PATIENTS WITH RECURRENT GLIOBLASTOMA FOLLOWING PROGRESSION ON ANTI-ANGIOGENIC THERAPY
143. A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study
144. Abstract CT314: Interim results from a phase I/II trial of TPI 287, a novel brain penetrable antimicrotubule agent, in combination with bevacizumab for the treatment of recurrent glioblastoma
145. Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma
146. Palliative and end-of-life care in glioblastoma: defining and measuring opportunities to improve care.
147. Wireless transcutaneous electric nerve stimulation (TENS) for chemotherapy-induced peripheral neuropathy (CIPN): A proof-of-concept, placebo-controlled, randomized clinical trial (RCT).
148. Clinical Features, Treatment, and Survival of Secondary Central Nervous System Lymphoma
149. Application of a validated predictive model for venous thrombo-embolism in cancer to patients with glioblastoma.
150. Diagnosis of Primary CNS Melanoma With Neuroimaging
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.